Podcast: Exploring Migraine Research, Treatment and Stigma
Dr.Teshamae Monteith sheds light on groundbreaking research and emerging treatment options reshaping the way we think about migraine.
In the latest episode of “Inside U Miami Medicine,” we delve into the complex and often misunderstood world of migraine — a disabling neurologic disorder that affects 40 million people globally.
Despite its prevalence, this common disease remains deeply stigmatized.
Teshamae Monteith, M.D., chief of the Headache Division at the University of Miami Miller School of Medicine, sheds light on groundbreaking research and emerging treatment options that aim to reshape the way we think about and treat migraine. The episode begins by exploring a key neuropeptide, calcitonin gene-related peptide (CGRP), which has been identified as a culprit in migraine attacks.
“When there is a migraine attack, there are numerous peptides that are released,” said Dr. Monteith, also a professor of clinical neurology at the Miller School. “And we saw clearly that there was a relationship between CGRP and migraine pain.”
Dr. Monteith also shares pharmaceutical innovations and highlights the potential of non-invasive electrical neuromodulation devices that are designed to prevent migraine. These devices use electrical impulses to either inhibit or facilitate neural activity, providing a new avenue for treatment.
Join us as we dive deep into the science, stigma and future of migraine treatment in this compelling episode, offering both hope and actionable insights for those affected by this pervasive disorder.
Tags: Dr. Teshamae Monteith, headache medicine, Inside U Miami Medicine, migraine, neurology, USNWR Neuro